Back

Biological Therapy for Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety

2025-10-19 respiratory medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundThe predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, although numerous studies have shown that eosinophilic inflammation contributes significantly to COPD. Eosinophilic COPD patients are characterized by a greater number of total exacerbations and higher hospitalization rates. Biological therapy targets multiple steps in eosinophilic inflammation, providing a promising approach to reduce exacerbation frequency and mortality. ObjectiveTo...

Predicted journal destinations